USFDA study shows Evusheld retains neutralising activity against Omicron: AstraZeneca

in health •  3 years ago 

image.png

Evusheld is the first long-acting antibody to receive emergency use authorisation in the US for pre-exposure prophylaxis of COVID-19, in addition to authorisations in other countries, and the drug firm is now working with regulators on applications for the use of Evusheld in treating COVID-19, he added. The Omicron variant was not in circulation during the Evusheld clinical trials

health covid vaccine astrazeneca
3 years ago by

Downvoting a post can decrease pending rewards and make it less visible. Common reasons:

  • Disagreement on rewards
  • Fraud or plagiarism
  • Hate speech or trolling
  • Miscategorized content or spam

Submit
$0.00
    0
    Authors get paid when people like you upvote their post.
    If you enjoyed what you read here, create your account today and start earning FREE STEEM!